← FDA DRUG APPROVALS

FDA ANDA · ANDA065407

TOBRAMYCIN

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA065407
TYPE
ANDA
ORIGINAL APPROVAL
2008-03-11
LATEST ACTION
2023-02-10
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

TOBRAMYCIN SULFATEPrescription
TOBRAMYCIN SULFATE EQ 40MG BASE/ML · INJECTABLE · INJECTION

Approval history

2023-02-10Labeling · Supplement 21 · standardAP
2023-01-18Labeling · Supplement 12 · standardAP
2023-01-18Labeling · Supplement 13 · standardAP
2014-10-24Labeling · Supplement 5 · standardAP
2014-04-23Labeling · Supplement 4 · standardAP
2008-03-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →